According to key opinion leaders (KOLs) interviewed by GlobalData, the prevalence of HIV will reduce in the future, partly due to better treatment options, the availability of PrEP, and the development of prophylactic vaccines.
Tag Archive for: Phase II
Boehringer Ingelheim on Monday revealed new Phase II data for its investigational GLP-1/glucagon receptor dual agonist survodutide, showing that it could elicit significant improvements in patients with metabolic dysfunction-associated steatohepatitis.